Cardinal Health stock (US14149Y1082): JPMorgan raises price target to $215

JPMorgan Chase & Co. has issued a new $215 price target for Cardinal Health (NYSE:CAH) shares, amid recent trading activity and strong value metrics highlighted by Zacks.

Cardinal Health stock experienced notable attention after JPMorgan Chase & Co. raised its price target to $215.00 per share, as reported on MarketBeat on May 11, 2026. The NYSE:CAH ticker also saw a 7.8% decline in a recent session, prompting questions about next moves, according to MarketBeat as of 05/11/2026. Zacks noted CAH's Zacks Rank #2 (Buy) and Value grade of A on the same date.

As of: 11.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Cardinal Health
• Sector/industry: Medical Distribution
• Headquarters/country: United States
• Core markets: US, Canada
• Key revenue drivers: Pharmaceuticals, Medical Products
• Home exchange/listing venue: NYSE (CAH)
• Trading currency: USD

Cardinal Health: core business model

Cardinal Health operates as a leading distributor of pharmaceuticals and medical products in the US market. The company serves hospitals, pharmacies, and healthcare providers through its two main segments: Pharmaceutical and Medical. In the fiscal year ended June 30, 2025, it reported total revenue of $226.8 billion, per its annual report published in August 2025. This scale positions it as a key player for US investors tracking healthcare logistics amid rising drug demand.

The Pharmaceutical segment handles brand-name and generic drugs, contributing over 75% of revenue. Medical focuses on devices, apparel, and services. Cardinal Health's at-home solutions also support US patients, enhancing relevance for domestic portfolios.

Main revenue and product drivers for Cardinal Health

Pharmaceutical distribution drives the bulk of Cardinal Health's revenue, with generics gaining share amid US cost pressures. Key products include opioids managed through its OptumRx partnership and nuclear pharmacy services. Medical revenue stems from gloves, gowns, and surgical kits, boosted by post-pandemic demand, as noted in Q1 fiscal 2026 results published September 2025.

US healthcare spending, projected at $4.9 trillion in 2026 by CMS data from December 2025, underpins growth. Cardinal Health's 20% US market share in drug distribution provides stability for NYSE-listed exposure.

Industry trends and competitive position

The US medical distribution sector faces margin squeezes from drug pricing reforms but benefits from volume growth. Cardinal Health competes with McKesson and Cencora, holding a strong #2 position by revenue. Its focus on specialty pharma and home infusion aligns with aging US demographics, per IQVIA sector report dated March 2026.

Why Cardinal Health matters for US investors

Listed on NYSE, Cardinal Health offers US investors direct exposure to healthcare supply chains critical to the world's largest market. With 90%+ revenue from North America, it mirrors US economic health, including pharmacy benefit manager trends and hospital consolidations.

Conclusion

Cardinal Health continues to navigate a dynamic US healthcare landscape with robust distribution infrastructure. Recent analyst updates like JPMorgan's $215 target and Zacks' value endorsement signal market interest, alongside trading fluctuations. Investors monitor earnings and sector trends for ongoing developments.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.